AGC unveils German expansion plans as gene and cell therapy manufacturing competition heats up
AGC Biologics is significantly expanding a German site focusing on cell and gene therapies.
The Seattle company will add another cGMP manufacturing line at its Heidelberg facilities, which already feature 100-liter and 1,000-liter manufacturing capacities for microbial protein and cell and gene therapy. The site will add more warehouse capacity too, which AGC says will help the company prepare for the rapid increase in demand.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 120,500+ biopharma pros reading Endpoints daily — and it's free.